Safe and broad-spectrum α2AAR agonist act as an oral analgesic
Non-opioid analgesics development is challenging and α2A-adrenergic receptor (α2AAR) as a target is hindered by side effects.
The researchers discovered a α2AAR agonist, CC10137, that produces a robust, dose-dependent anti-allodynic effect across eight murine pain models, without causing sedation, hypotension, or hypothermia.
Administered in combination with morphine, CC10137 reversed allodynia and the synergy was replicated in a cancer pain model.
CC10137 had no effect on spinal nociceptive reflex unlike morphine and thus could selectively suppress allodynia with a favorable safety profile, highlighting its potential as a standalone or combination therapeutic for chronic pain.
https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00281-8
